论文部分内容阅读
目的 通过监测肾移植术后患者环孢霉素A(CsA)的全血浓度,探讨CsA在霉酚酸酯(MMF)参与的三联免疫抑制用药方案中的理想治疗窗.方法 用特异性荧光偏振免疫法测定CsA全血浓度.依术后时间及三联免疫抑制方案的不同分组,并对CsA治疗窗进行比较.结果 MMF方案中CsA在肾移植术后＜1mon、1~3mon、3~6mon的理想治疗窗分别为150~300μg·L~(-1)120~260μg·L~(-1)和100~225μg·L(-1).结论 MMF方案优于经典方案,可安全、有效预防移植术后的排异和毒性反应.
Objective To investigate the ideal therapeutic window of CsA in triple immunosuppressive regimens with mycophenolate mofetil (MMF) by monitoring the whole blood concentration of cyclosporine A (CsA) in patients after renal transplantation.Methods Using specific fluorescence polarization The concentration of CsA whole blood was determined by immunohistochemistry, and the time of treatment and different groups of triple immunosuppressive regimens were compared and the CsA therapeutic windows were compared.Results CsA in MMF regimen was less than 1mon, 1 ~ 3mon, 3 ~ 6mon after renal transplantation The best therapeutic window was 150 ~ 300μg · L -1 120 ~ 260μg · L -1 and 100 ~ 225μg · L -1, respectively.Conclusion MMF is better than the classic one, which can be safely and effectively prevented from transplanting Postoperative rejection and toxicity.